Last reviewed · How we verify
Risperidone prolonged release
Risperidone prolonged release, marketed by Janssen-Cilag Ltd., is a well-established treatment in its class. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential competition from generic entries post-patent expiry.
At a glance
| Generic name | Risperidone prolonged release |
|---|---|
| Also known as | - Risperdal consta |
| Sponsor | Janssen-Cilag Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (PHASE1)
- Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM® (PHASE1)
- Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone prolonged release CI brief — competitive landscape report
- Risperidone prolonged release updates RSS · CI watch RSS
- Janssen-Cilag Ltd. portfolio CI